logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Avatrombopag in addition to standard of care for chronic immune thrombocytopenia

< Back

Avatrombopag in addition to standard of care for chronic immune thrombocytopenia

Drugs

Haematology and Blood Products

July 2020


Avatrombopag is currently in clinical development for the treatment of chronic immune thrombocytopenia (ITP) in patients who have had an insufficient response to previous treatment. ITP is an auto-immune disease that arises when the body’s immune system attacks platelet cells resulting in a decreased number of platelets (platelet count). Platelets help blood to clot following damage to a blood vessel wall so if there is a decreased number of platelets there is an increased risk of frequent bleeding or severe bleeding. This results in the symptoms associated with ITP such as petechial (pin prick rash of blood spots), bruising, nosebleeds, gum bleeds, fatigue and heavy periods.

Avatrombopag is given as an oral tablet and works by mimicking the action of a hormone called thrombopoietin (TPO) which is responsible for causing pre-curser cells to mature into platelets. Avatrombopag binds to TPO receptors resulting in increased platelet production and increased platelet count. Results from clinical studies have demonstrated that avatrombopag is safe and efficacious. If licensed, avatrombopag could offer an additional treatment option for patients with chronic ITP who have had limited response to previous therapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts